Prevalence and risk factors of measles seronegativity in a cohort of <scp>HIV</scp>‐positive subjects: a retrospective study

Dauby, Nicolás; Martin, Charlotte; Hainaut, Marc; Grammens, Tine; Wijngaert, Sigi Van den; Delforge, Marc; Wit, Stéphane De

doi:10.1111/hiv.12610

Cited by 6 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies performed in Europe that have assessed rubella seronegativity in HIV-infected subjects did not specifically assess the impact of perinatal infection [9,10]. We and another group from Ireland have recently identified that vertical HIV transmission was a risk factor for measles seronegativity in young HIV-positive adults [11,12].…”

Section: Discussionmentioning

confidence: 95%

High rate of rubella seronegativity in perinatally-infected HIV women of childbearing age: A case-control study

Beun

Grammens

Hainaut

et al. 2019

Vaccine

Self Cite

View full text Add to dashboard Cite

Rubella infection is a vaccine preventable disease. Maternal infection during pregnancy may lead to congenital infection and severe foetal malformations. Thanks to antiretroviral therapy, perinatally HIVinfected women have better prognosis and are now experiencing pregnancy. We evaluated the rate of rubella seronegativity in a cohort of HIV perinatally-infected women of childbearing age. A high rate of seronegativity was found in this group as compared to age-matched non-perinatally infected HIVinfected women (34.5% vs 6.90%, p < 0.01). MMR administration before rubella testing was identified in 75.8% of perinatally-infected women (22/29) with a mean of 2 doses (range: 1-3 doses). HIV perinatally-infected women of childbearing age should be screened repeatedly for rubella immunity.

show abstract

Section: Discussionmentioning

confidence: 95%

High rate of rubella seronegativity in perinatally-infected HIV women of childbearing age: A case-control study

Beun

Grammens

Hainaut

et al. 2019

Vaccine

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previous studies have reported a more rapid decline in vaccine-induced antibody response in pHIV subjects compared with HIV-uninfected children and compared with PWH acquired during adulthood [9,20]. Higher seronegativity for the measles and rubella components of the MMR vaccine has been reported [4,7], and guidelines for the management of pHIV subjects recommend screening every 3–5 years for measles and rubella immunoglobulin G (IgG) [2]. The current lack of availability of testing for yellow fever NAbs limits the possibility of such recommendations for yellow fever but could be considered for pHIV subjects.…”

Section: Discussionmentioning

confidence: 99%

“…Significant disease and death still occur despite apparent immune reconstitution, and part of this is attributable to vaccine-preventable diseases [2]. Several studies have demonstrated important immunization gaps in this population with pHIV [2,[4][5][6][7], partly because lower antibody levels and more rapid waning over time that are frequently reported despite ARTuptake [8][9][10][11][12][13]. HIV viral replication in lymphoid tissue from an early age, before immunological maturation, results in multicomponent immunological impairment [2].…”

Section: Introductionmentioning

confidence: 99%

Seroconversion and persistence of neutralizing antibody response after yellow fever vaccination in patients with perinatally acquired HIV infection

Martin

Domingo

Hainaut

et al. 2022

Aids

View full text Add to dashboard Cite

Objective(s):To describe the dynamics of neutralizing antibody (NAbs) response after yellow fever (YF) vaccine in young adults and adolescents with perinatally acquired HIV (pHIV).Design: A retrospective cross-sectional study at three time points around YF vaccination and a matched case-control comparison of NAbs titers several years after YF vaccination. Methods: We selected patients who had both documented YF vaccination and perinatally acquired HIV (n ¼ 46). The NAbs titers were measured in plasma samples from the following three time points: during the two years before (TP0), within the year after (TP1) and >1 year after (TP2) administration of the YF vaccine. The impact of perinatal infection was assessed by comparing pHIV YF vaccinees with 44 controls infected with HIV during adulthood. Results:The median time between the YF vaccine and TP1 and TP2 was 123 days and 7.3 years, respectively. After YF vaccination, 85% of vaccinees experienced seroconversion. The proportion of pHIV patients with NAbs above the protective threshold was stable between TP1 and TP2 (91% and 86%, respectively) but levels of NAbs decreased significantly between TP1 and TP2 (P ¼ 0.0122). The case-control analysis found slightly higher geometrical mean titers (GMT) in pHIV than patients infected during adulthood.Conclusions: Patients with pHIV showed high seroconversion rate and NAbs persistence at levels above the protective threshold after first YF vaccination. However, a decline in antibody levels over time suggests that at least one revaccination may be necessary to maintain circulating antibodies, contrary to recommendations for the general population.

show abstract

“…We read with interest the article by Dauby et al which highlighted an approximately 5-fold increase compared with HIV-infected individuls born before 1970 in the risk of measles seronegativity in HIV-infected subjects born after 1970 [1].…”

Section: Dear Sirmentioning

confidence: 99%

Fatal measles as AIDS presentation in Italy

et al. 2019

View full text Add to dashboard Cite

Prevalence and risk factors of measles seronegativity in a cohort of HIV‐positive subjects: a retrospective study

Abstract: HIV-infected subjects born after 1970 and vertically infected subjects should be screened for measles seropositivity.

Cited by 6 publications

References 18 publications

High rate of rubella seronegativity in perinatally-infected HIV women of childbearing age: A case-control study

High rate of rubella seronegativity in perinatally-infected HIV women of childbearing age: A case-control study

Seroconversion and persistence of neutralizing antibody response after yellow fever vaccination in patients with perinatally acquired HIV infection

Fatal measles as AIDS presentation in Italy

Contact Info

Product

Resources

About